AX-2026-043105
Epitalon · 20 mg declared · Zhuhai Kerui Biotechnology Co., Ltd. · lot KP-2508-Y5884
- Report ID
- AX-2026-043105
- Compound
- Epitalon
- Compound class
- Short bioregulator peptides
- Supplier
- KP — Zhuhai Kerui Biotechnology Co., Ltd.
- Batch / lot
- KP-2508-Y5884
- Declared label claim
- 20mg
- Laboratory
- VendorInvestigate
- Assay date
- 21 Jan 2026
- Submitted
- 23 Jan 2026
- Quarter
- 2026-Q1
- Submitter
- p.hovland
- Sample provenance
- Buyer-sourced
Results
Measured against the index acceptance specification for the short bioregulator peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.
| Parameter | Method | Result | Unit | Index spec | |
|---|---|---|---|---|---|
| Purity | RP-HPLC, 32 min gradient, 214 nm | 98.07 | % area | ≥ 99.0 | FAIL |
| Total impurities | RP-HPLC, sum of reported peaks | 1.93 | % area | ≤ 1.0 | FAIL |
| Largest single impurity | RP-HPLC — Ala-Glu-Asp tripeptide (−57 Da) | 1.00 | % area | ≤ 1.00 | PASS |
| Identity — theoretical monoisotopic mass | calculated from molecular formula | 390.1387 | Da | — | NOT TESTED |
| Identity — observed monoisotopic mass | LC-MS, high resolution (ESI-TOF/QTOF) | 390.1395 | Da | — | NOT TESTED |
| Mass accuracy | observed vs theoretical | +2.1 | ppm | ± 20 | PASS |
| Total peptide content | by difference from the gravimetric mass balance | 83.08 | %w/w | — | NOT TESTED |
| Target-compound content | total peptide content × purity | 81.48 | %w/w | — | NOT TESTED |
| Gross fill (as weighed) | five-place balance, under nitrogen | 25.42 | mg | 20 mg declared | NOT TESTED |
| Recovered target peptide | gross fill × target content | 20.712 | mg | 20 mg claim | NOT TESTED |
| Recovery against label claim | recovered ÷ claim | 103.6 | % | 90.0 – 110.0 | PASS |
| Water content | Karl Fischer, coulometric, duplicate | 7.50 | % | ≤ 12.0 | PASS |
| Counter-ion (acetate) | anion-exchange ion chromatography | 8.65 | % | ≤ 10.0 | PASS |
| Residual solvent + inorganic residue | estimated — see /methods/residual-solvents-q3c/ | 0.77 | % | — | NOT TESTED |
| Endotoxin | not ordered on this submission | not determined | — | ≤ 5.0 | NOT TESTED |
| Sterility | membrane filtration, USP <71>, 14 d | No growth at 14 d | — | no growth | PASS |
| Appearance | visual, diffuse light, black and white background | White lyophilised cake, intact | — | white to off-white intact cake | PASS |
| Reconstitution clarity | reconstituted per submitter procedure | Clear, colourless, no visible particulates | — | clear, no visible particulates | PASS |
| pH (reconstituted, 1 mg/mL) | potentiometric, two-point calibration | 6.12 | — | 2.5 – 8.0 | PASS |
| Retention time (observed) | RP-HPLC, 32 min gradient | 4.87 | min | 4.90 ± 0.20 (normalised) | PASS |
| Peak asymmetry (10 % height) | Ph. Eur. 2.2.46 | 1.16 | — | 0.80 – 1.50 | PASS |
| Plate count, main peak | N = 5.54 (t/w½)² | 63,448 | — | ≥ 20,000 | PASS |
| Resolution to nearest impurity | vs β-Asp isomer | 1.35 | — | no index criterion | REPORTED |
Chromatogram and peak integration
The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.
| # | Peak | RT | Area (µV·s) | % area | Δ mass (Da) |
|---|---|---|---|---|---|
| 1 | Epitalon — main peak | 4.87 | 4,766,506 | 98.07 | — |
| 2 | Ala-Glu-Asp tripeptide (−57 Da) | 4.66 | 48,603 | 1.00 | -57.021 |
| 3 | aspartimide (−18 Da) | 5.00 | 18,469 | 0.38 | -18.011 |
| 4 | diketopiperazine (−18 Da) | 5.04 | 15,067 | 0.31 | -18.011 |
| 5 | β-Asp isomer | 4.76 | 11,665 | 0.24 | 0.000 |
| Closure check — purity + Σ impurities | 100.00 | CLOSES | |||
Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.
Mass spectrum and identity
Theoretical monoisotopic mass 390.1387 Da, computed from C14H22N4O9. All ppm figures on this site are against monoisotopic values — see why that matters.
| Charge | Theoretical m/z | Observed m/z | Δ m/z | Rel. abundance (%) |
|---|---|---|---|---|
| 1+ | 391.1460 | 391.1468 | 0.0008 | 100.0 |
Gravimetric mass balance
Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.
| Component | Determination | %w/w of cake |
|---|---|---|
| Water | Karl Fischer | 7.50 |
| Counter-ion (acetate) | ion chromatography | 8.65 |
| Residual solvent + inorganic residue | estimated | 0.77 |
| Total peptide content | by difference | 83.08 |
| Total | 100.00 CLOSES | |
Supplier certificate, as declared
The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.
| Figure | Supplier COA | This report | Index note |
|---|---|---|---|
| Purity (% area) | 98.43 | 98.07 | divergence -0.15 pp vs batch median |
| Total impurities (% area) | 1.57 | 1.93 | |
| Largest single impurity (% area) | not stated | 1.00 | |
| Water (%) | 6.1 | 7.50 | |
| Counter-ion (%) | not stated | 8.65 | |
| Peptide content (%w/w) | 89.1 | 83.08 | |
| Endotoxin (EU/mg) | not stated | not determined | |
| Method stated on certificate | YES | — | column, gradient and wavelength given |
Provenance and caveats
Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.
- Sample provenance
- Buyer-sourced
- Evidentiary weight
- Strongest available evidence in this index.
- Chain of custody
- Retail purchase → submitter (−20 °C, 19 d) → laboratory (courier, dry ice, 10 d) → assay.
- Assay date
- 21 Jan 2026
- Submitted to the index
- 23 Jan 2026
- Laboratory
- VendorInvestigate, Riga, Latvia
- Method basis
- 32 min gradient · high-resolution MS
- Verification status
- METHOD LIMITED
Annotations 2
Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.
Related records
Same batch — lot KP-2508-Y5884 n=6
| Report | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|
| AX-2026-043106 | KP-2508-Y5884 | PeptideMeter | 2026-Q1 | 98.22 | 8.71 | 98.4 | Buyer-sourced | 0 | FAIL |
| AX-2026-043107 | KP-2508-Y5884 | Medutest | 2026-Q1 | 99.20 | 7.93 | 96.6 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043108 | KP-2508-Y5884 | Kestrel | 2026-Q1 | 99.04 | 7.77 | 104.2 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043109 | KP-2508-Y5884 | Janoshik | 2026-Q1 | 98.39 | 8.24 | 99.8 | Buyer-sourced | 0 | FAIL |
| AX-2026-043110 | KP-2508-Y5884 | PeptideMeter | 2026-Q1 | 98.77 | 7.55 | — | Supplier-supplied | 1 | FAIL |
Cross-sections
| Report | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042008 | AMB | AMB-2602-Y6433 | Janoshik | 2026-Q3 | 99.30 | 8.75 | 105.1 | Buyer-sourced | 0 | PASS |
| AX-2026-042009 | AMB | AMB-2602-Y6433 | VendorInvestigate | 2026-Q3 | 99.16 | 8.62 | 102.3 | Buyer-sourced | 0 | FAIL |
| AX-2026-042010 | AMB | AMB-2602-Y6433 | Janoshik | 2026-Q3 | 99.09 | 8.20 | 103.4 | Laboratory-retained | 0 | FAIL |
| AX-2026-042007 | AMB | AMB-2602-Y6433 | Janoshik | 2026-Q3 | 99.42 | 8.62 | 93.8 | Buyer-sourced | 0 | FAIL |
| AX-2026-042468 | Homopeptide | HOMO-2512-A5108 | Janoshik | 2026-Q2 | 99.93 | 7.81 | 100.8 | Buyer-sourced | 0 | PASS |
| AX-2026-042463 | Homopeptide | HOMO-2512-A5108 | Janoshik | 2026-Q2 | 99.93 | 7.68 | 93.2 | Buyer-sourced | 0 | FAIL |
| AX-2026-042041 | HYB | HYB-2603-U7133 | Janoshik | 2026-Q2 | 99.65 | 6.82 | 95.3 | Buyer-sourced | 0 | FAIL |
| AX-2026-042470 | Homopeptide | HOMO-2512-A5108 | Janoshik | 2026-Q2 | 99.63 | 7.99 | — | Buyer-sourced | 0 | FAIL |
| Report | Compound | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-043095 | Retatrutide | KP-2607-H5774 | Janoshik | 2026-Q3 | 95.81 | 5.48 | 105.2 | Buyer-sourced | 0 | FAIL |
| AX-2026-043094 | Retatrutide | KP-2607-H5774 | PeptideMeter | 2026-Q3 | 96.32 | 6.40 | — | Buyer-sourced | 0 | FAIL |
| AX-2026-043096 | Retatrutide | KP-2607-H5774 | VendorInvestigate | 2026-Q3 | 96.48 | 6.05 | 104.9 | Buyer-sourced | 0 | FAIL |
| AX-2026-043090 | Retatrutide | KP-2607-H5774 | Janoshik | 2026-Q3 | 96.46 | 5.81 | — | Buyer-sourced | 0 | FAIL |
| AX-2026-043091 | Retatrutide | KP-2607-H5774 | Janoshik | 2026-Q3 | 96.13 | 5.94 | — | Buyer-sourced | 0 | FAIL |
| AX-2026-043077 | TB-500 | KP-2605-C5214 | Janoshik | 2026-Q2 | 99.61 | 5.64 | 90.2 | Buyer-sourced | 0 | PASS |
| AX-2026-043093 | Retatrutide | KP-2607-H5774 | Janoshik | 2026-Q3 | 96.54 | 5.54 | — | Buyer-sourced | 0 | PASS |
| AX-2026-043092 | Retatrutide | KP-2607-H5774 | Medutest | 2026-Q3 | 96.64 | 6.12 | — | Buyer-sourced | 1 | FAIL |